22994-85-0 Benznidazole 22994-85-0 Benznidazole 22994-85-0 Benznidazole
Product Name: Benznidazole
Synonyms: benznidazole;benzonidazole;n-benzyl-2-(nitroimidazol-1-yl)-acetamid;n-benzyl-2-nitro-1-imidazoleacetamide;n-benzyl-2-nitro-imidazole-1-acetamid;n-benzyl-2-nitroimidazole-1-acetamide;radanil;ro71051
CAS: 22994-85-0
MF: C12H12N4O3
MW: 260.25
EINECS:
Product Categories: Heterocyclic Compounds;Building Blocks;Heterocyclic Building Blocks;Imidazoles
Mol File: 22994-85-0.mol
Benznidazole Chemical Properties
Melting point 189-192 °C(lit.)
density 1.35±0.1 g/cm3(Predicted)
solubility methanol: soluble50mg/mL, clear, colorless to yellow
pka 14 +-.0.46(Predicted)
Water Solubility 0.4g/L(temperature not stated)
Merck 13,1085
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
WGK Germany 3
RTECS NI3340000
Benznidazole Usage And Synthesis
Uses Benznidazole (BNZ) is traditionally used to treat Chagas disease caused by Trypanosoma cruzi. The drugs used for the treatment of this disease, Nifurtimox and Benznidazole, are toxic and present sever e side effects.
Definition ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.
Antimicrobial activity It exhibits antiprotozoal activity, particularly against Trypanosoma cruzi.
Pharmaceutical Applications A synthetic 2-nitroimidazole, formulated for oral administration. Solubility in water 400 mg/L.
Pharmacokinetics Oral bioavailability :High
Cmax 100 mg oral :2.2–2.8 mg/L after 3–4 h
Plasma half-life:10.5–13.6 h
Volume of distribution:c. 0.56 L/kg
Plasma protein binding: c. 44%
The 2-nitro group undergoes reduction to the amine and hydrolysis to the hydroxy derivative.
Clinical Use N-Benzyl-2-nitroimidazole-1-acetamide (Radanil, Rochagan)is a nitroimidazole derivative that is used for the treatment ofChagas disease. It is not available in the United States but isused extensively in South America. The effectiveness of benznidazoleis similar to that of nifurtimox. Therapy forAmerican trypanosomiasis with oral benznidazole requiresseveral weeks and is frequently accompanied by adverse effectssuch as peripheral neuropathy, bone marrow depression,and allergic-type reactions.
Clinical Use Benznidazole is used in treatment of South American trypanosomiasis (Chagas disease).
Side effects Adverse effects are more common in the elderly and include nausea, vomiting, abdominal pain, peripheral neuropathy and severe skin reactions.
Product Name: Benznidazole
Synonyms: benznidazole;benzonidazole;n-benzyl-2-(nitroimidazol-1-yl)-acetamid;n-benzyl-2-nitro-1-imidazoleacetamide;n-benzyl-2-nitro-imidazole-1-acetamid;n-benzyl-2-nitroimidazole-1-acetamide;radanil;ro71051
CAS: 22994-85-0
MF: C12H12N4O3
MW: 260.25
EINECS:
Product Categories: Heterocyclic Compounds;Building Blocks;Heterocyclic Building Blocks;Imidazoles
Mol File: 22994-85-0.mol
Benznidazole Chemical Properties
Melting point 189-192 °C(lit.)
density 1.35±0.1 g/cm3(Predicted)
solubility methanol: soluble50mg/mL, clear, colorless to yellow
pka 14+-.0.46(Predicted)
Water Solubility 0.4g/L(temperature not stated)
Merck 13,1085
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
WGK Germany 3
RTECS NI3340000
Benznidazole Usage And Synthesis
Uses Benznidazole (BNZ) is traditionally used to treat Chagas disease caused by Trypanosoma cruzi. The drugs used for the treatment of this disease, Nifurtimox and Benznidazole, are toxic and present sever e side effects.
Definition ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.
Antimicrobial activity It exhibits antiprotozoal activity, particularly against Trypanosoma cruzi.
Pharmaceutical Applications A synthetic 2-nitroimidazole, formulated for oral administration. Solubility in water 400 mg/L.
Pharmacokinetics Oral bioavailability :High
Cmax 100 mg oral :2.2–2.8 mg/L after 3–4 h
Plasma half-life:10.5–13.6 h
Volume of distribution:c. 0.56 L/kg
Plasma protein binding: c. 44%
The 2-nitro group undergoes reduction to the amine and hydrolysis to the hydroxy derivative.
Clinical Use N-Benzyl-2-nitroimidazole-1-acetamide (Radanil, Rochagan)is a nitroimidazole derivative that is used for the treatment ofChagas disease. It is not available in the United States but isused extensively in South America. The effectiveness of benznidazoleis similar to that of nifurtimox. Therapy forAmerican trypanosomiasis with oral benznidazole requiresseveral weeks and is frequently accompanied by adverse effectssuch as peripheral neuropathy, bone marrow depression,and allergic-type reactions.
Clinical Use Benznidazole is used in treatment of South American trypanosomiasis (Chagas disease).
Side effects Adverse effects are more common in the elderly and include nausea, vomiting, abdominal pain, peripheral neuropathy and severe skin reactions.
CAS NO:114435-02-8
CAS NO:1541-67-9
CAS NO:423-55-2
CAS NO:1438-82-0
CAS NO:124-41-4
CAS NO:409071-16-5
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View